Successful use of Campath-1H in the treatment of steroid refractory liver GvHD [8]

Bone Marrow Transplantation

Volumn 34, Issue 3, 2004, Pages 285-287

  Wandroo, F ^a   Auguston, B ^a   Cook, M ^a   Craddock, C ^a   Mahendra, P ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEVOFLOXACIN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOTRANSPLANTATION; CASE REPORT; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEGIONELLA; LETTER; LIVER BIOPSY; LIVER DISEASE; MALE; PNEUMONIA; PRIORITY JOURNAL; SIBLING; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LIVER DISEASES; MALE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 4344621575     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704573     Document Type: Letter

References (10)

1. Biggs JC, Szer J, Crilley P et al. Treatment of chronic myeloid leukaemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80: 1352-1357.
2. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute GvHD after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
3. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft versus host disease: secondary treatment. Blood 1991; 77: 1821-1828.
4. Remberger M, Aschan J, Barkholt L et al. Treatment of acute graft-versus-host disease with antithymocyte globulin. Clin Transplant 2001; 15: 147-153.
5. Abhyankar S, Godder K, Christiansen N et al. Treatment of resistant acute and chronic graft-versus-host disease with mycophenolate mofetil. Blood 1998; 92 (Suppl.): 340b (abstract 4467).
6. Farag SS, Bruner R. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 2003; 30: 509-519.
7. Mufti GJ, Fishlock K, Arno M et al. Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with Campath-1H. Blood 2001; 98: 2048 (abstract 1543).
8. Naparstek E, Or R, Nagler A et al. T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
9. Varadi G, Reuven OR, Slavin S et al. In vivo Campath-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. Am J Haematol 1996; 52: 236-237.
10. Carella AM, Beltrami G, Scalzulli PR et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGvHD). BMT 2004; 33: 131-132.